Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Portfolio Pulse from
Apellis Pharmaceuticals (APLS) reported a wider-than-expected loss for Q3 2024, with earnings and revenues missing estimates. However, the company's product Syfovre contributed to year-over-year revenue growth.
November 06, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Apellis Pharmaceuticals reported a wider-than-expected loss for Q3 2024, missing both earnings and revenue estimates. Despite this, their product Syfovre contributed to a year-over-year increase in revenues.
The wider-than-expected loss and missed estimates are likely to negatively impact APLS's stock price in the short term. However, the positive contribution of Syfovre to revenue growth may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100